Eyebiotech
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
Eyebiotech Limited (EyeBio) was a clinical-stage ophthalmology biotechnology company founded in August 2021 by David Guyer and Anthony P. Adamis together with SV Health Investors, building a portfolio of next-generation therapies for eye diseases. Its lead asset Restoret (EYE103/MK-3000) is an intravitreally delivered, tri-specific antibody acting as an agonist of the Wnt signaling pathway, designed to resolve retinal fluid and improve visual acuity in wet age-related macular degeneration and diabetic macular edema. The company raised a $65 million Series A in 2022, extended to $130 million in 2023, and operated across London and New York.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Founded
EyeBio was founded in August 2021 by David Guyer and Anthony P. Adamis with SV Health Investors, launching to build a diversified pipeline of ocular therapies.
- Series A
The company closed a $65 million Series A led by SV Health Investors, alongside Samsara BioCapital and Jeito Capital, with participation from MRL Ventures.
- Series A extended to $130M
EyeBio closed a $65 million extension, bringing total Series A financing to $130 million with new investors Bain Capital Life Sciences, Omega Funds, and Vertex Ventures HC.
- Acquired by Merck
Merck announced in May 2024 its acquisition of EyeBio, making it a wholly owned subsidiary; Merck initiated the Phase 2b/3 BRUNELLO trial of Restoret (MK-3000) for diabetic macular edema in September 2024.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.